| Symbol | ARMP |
|---|---|
| Name | ARMATA PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 4503 GLENCOE AVENUE, MARINA DEL REY, California, 90292, United States |
| Telephone | +1 858 829-0829 |
| Fax | — |
| — | |
| Website | https://www.armatapharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Further, the company is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing. Additional info from NASDAQ: |
(99% Neutral) ARMATA PHARMACEUTICALS, INC. (ARMP) Announces Update on Collaboration with UNITED STATES
Read more(99% Neutral) ARMATA PHARMACEUTICALS, INC. (ARMP) Reports Q1 2026 Financial Results
Read moreArmata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results
Read moreNew Form 10-K - Armata Pharmaceuticals, Inc. <b>Filed:</b> 2026-03-25 <b>AccNo:</b> 0001104659-26-034532 <b>Size:</b> 9 MB
Read more(10% Negative) ARMATA PHARMACEUTICALS, INC. (ARMP) Announces Delay in results Development Timeline Due to Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment
Read moreArmata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update
Read moreKyme Pierre 🔴 sold 1.0K shares of Armata Pharmaceuticals, Inc. (ARMP) at $10.54 Transaction Date: Mar 14, 2026 | Filing ID: 029712
Read moreDirector Birx Deborah 🔴 sold 4.9K shares of Armata Pharmaceuticals, Inc. (ARMP) at $10.54 Transaction Date: Mar 14, 2026 | Filing ID: 029711
Read moreDirector Kramer Robin 🟢 acquired 25.6K shares (1 derivative) of Armata Pharmaceuticals, Inc. (ARMP) at $11.61 Transaction Date: Mar 09, 2026 | Filing ID: 026589
Read moreKyme Pierre 🟢 acquired 183.1K shares (1 derivative) of Armata Pharmaceuticals, Inc. (ARMP) at $11.61 ($2.1M) Transaction Date: Mar 09, 2026 | Filing ID: 026588
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT03395769 | Individual Patient Expanded Access for AB-SA01, an Investigational Anti-Staphyl… | — | — | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT05184764 | Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in S… | Phase1 | Bacteremia | Completed | 2022-04-26 | 2025-01-14 | ClinicalTrials.gov |
| NCT03004365 | A Study to Evaluate the Safety and Microbiology of C16G2 Varnish Administered i… | Phase2 | Dental Caries | Completed | 2017-01-27 | 2017-03-29 | ClinicalTrials.gov |
| NCT02757755 | Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact … | Phase1 | Healthy Volunteers | Completed | 2016-05-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02044081 | Phase 2, Safety & Microbiology Study of C16G2 in Multiple Oral Gel &/or Mouth R… | Phase2 | Dental Caries | Completed | 2014-02-01 | 2014-08-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| AP-SA02 | BIOLOGICAL | Phase PHASE1 | Bacteremia | COMPLETED | NCT05184764 |
| AP-PA02 | BIOLOGICAL | Phase PHASE2 | Non-cystic Fibrosis Bronchiectasis | COMPLETED | NCT05616221 |
| AB-SA01 | BIOLOGICAL | Preclinical | — | NO_LONGER_AVAILABLE | NCT03395769 |
| AB-PA01 | BIOLOGICAL | Preclinical | — | NO_LONGER_AVAILABLE | NCT03395743 |
| Placebo Strip | OTHER | Phase PHASE2 | Dental Caries | COMPLETED | NCT03052842 |
| C16G2 Strip | DRUG | Phase PHASE2 | Dental Caries | COMPLETED | NCT03052842 |
| Placebo Varnish | DRUG | Phase PHASE2 | Dental Caries | COMPLETED | NCT03004365 |
| C16G2 Varnish | DRUG | Phase PHASE2 | Dental Caries | COMPLETED | NCT03004365 |
| Placebo (for Cohort 10^9) | BIOLOGICAL | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02757755 |
| Placebo (for Cohort 10^8) | BIOLOGICAL | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02757755 |
| AB-SA01 (10^9 PFU per phage) | BIOLOGICAL | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02757755 |
| AB-SA01 (10^8 PFU per phage) | BIOLOGICAL | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02757755 |
| C16G2 | DRUG | Phase PHASE2 | Dental Caries | COMPLETED | NCT03196219 |
| C16G2 Gel | DRUG | Phase PHASE2 | Dental Caries | COMPLETED | NCT02594254 |
| Placebo | OTHER | Phase PHASE2 | Non-cystic Fibrosis Bronchiectasis | COMPLETED | NCT05616221 |
| C16G2 Rinse | DRUG | Phase PHASE2 | Dental Caries | COMPLETED | NCT02044081 |